United States - English - NLM (National Library of Medicine)

1st class pharmaceuticals, inc. - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a) - topical analgesic topical analgesic for temporary relieft of pain associated with minor burns, minor cuts, scrapes, insect bites or skin irritations. - if symptoms persist for more than seven days, discontinue use and consult physician.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg - carbamazepine extended-release capsules are indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvements than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general ). carbamazepine extended-release capsules are indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 1000 mg - levetiracetam tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. this product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in levetiracetam tablets. the abuse and dependence potential of levetiracetam has not been evaluated in human studies.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dexmedetomidine hydrochloride 0.1182 mg/ml equivalent to dexmedetomidine 0.1mg/ml - concentrate for injection - active: dexmedetomidine hydrochloride 0.1182 mg/ml equivalent to dexmedetomidine 0.1mg/ml excipient: sodium chloride water for injection - for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine hydrochloride ever pharma by continuous intubation in these patents should not exceed 24 hours. for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Malta - English - Medicines Authority

uni-pharma kleon tsetis pharmaceutical laboratories s.a. 14th km national road athens - lamia 1, gr-145 64 kifissia, greece - lozenge - flurbiprofen 8.75 mg - throat preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule - 10 milligram(s) - proton pump inhibitors; omeprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule - 20 milligram(s) - proton pump inhibitors; omeprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule, hard - 40 milligram(s) - proton pump inhibitors; omeprazole

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington's disease. tetrabenazine tablets are contraindicated in patients: •who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions (5.1)]. •with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)]. •taking monoamine oxidase inhibitors (maois). tetrabenazine tablets should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi. [see drug interactions (7.3)]. •taking reserpine . at least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets [see drug interactions (7.2)]. • taking deutetrabenazine or valbenazine [see drug interactions (7.7)]. teratogenic effects: risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine in pregnant women. administration of tetrabenazi

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - clorazepate dipotassium (unii: 63fn7g03xy) (clorazepic acid - unii:d51wo0g0l4) - clorazepate dipotassium 7.5 mg - clorazepate dipotassium tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. the effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. long-term studies in epileptic patients, however, have shown continued therapeutic activity. the physician should reassess periodically the usefulness of the drug for the individual patient. clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. clorazepate dipotassium tablets are contraindicated in patients with a known hypersensitivity to the drug and in those with acute narrow angle glaucoma.